Search

Your search keyword '"Guillevin, L"' showing total 2,940 results
Start Over Author "Guillevin, L"
2,940 results on '"Guillevin, L"'

1. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

Author

Aumaitre, H., Froguel, E., Caby, F., Dellion, S., Gerard, L., Lucht, F., Chirouze, C., Dupon, M., Schmit, Jl, Goujard, C., Allegre, T., Cazenave, B., Hittinger, G., De Truchis, P., Cailhol, J., Duvivier, C., Canestri, A., Bouchaud, O., Karmochkine, M., Salmon-Ceron, D., Zucman, D., Mortier, E., Tubiana, R., Girard, P.M., Pintado, C., Cabie, A., Rabier, V., Morlat, P., Neau, D., Genet, C., Makhloufi, D., Ronot, S Bregigeon, Ghosn, J., Reliquet, V., Perré, P., Pellegrin, Jl, Arvieux, C., Cheneau, C., Bernard, L., Delobel, P., Verdon, R., Jacomet, C., Piroth, L., Ajana, F., Bevilacqua, S., Debab, Y., Lecapitaine, A.L., Cotte, L., Mokhtari, S., Mercie, P., Poubeau, P., Garrait, V., Khuong, Ma, Beck-Wirth, G., Blum, L., Blanche, S., Boccara, F., Prazuck, T., Barbuat, C., Viard, J.P., Stegmann-Planchard, S., Martha, B., Treluyer, J.M., Dore, E., Gaud, C., Niault, M., Fernandes, E., Hitoto, H., Compagnucci, A., Elenga, N., Faye, A., Dollfus, C., Chace, A., Levine, M., Martha, S.A., Floch-Tudal, C., Kebaïli, K., Entz-Werle, N., Tricoire, J., Mazingue, F., Bolot, P., Brazille, P., Goetghebuer, T., Gennotte, A.F., Van Der Linden, D., Schmitz, V., Moutschen, M., Crenn-Hebert, C., Habibi, F., Coursol, A., Guesdon, E., Ceccaldi, P.F., Dehlinger – Paul, M., Pannier, E., Marcou, V., Elleau, C., Achkar, M., Vareil, M.O., Couderc, S., Routier, C., Bouldouyre, M.A., Selleret, L., Chabrol, A., Bellahcene, C., Pluchart, C., Yangui, A., Vignes, D., Alissa, A., Johnson, A., Lachassinne, E., Benbara, A., Karaoui, L., Bongain, A., Yakeu, B., Schmit, J.L., Cravello, L., Hubert, C., Faucher, P., Pinquier, D., Borie, C., Rocchi, D., Brunet-Cartier, C., Briandet, C., Brouard, J., Chalvon-Demersay, A., Rajguru, M., Billiemaz, K., Fresard, A., Moulin, A., Fialaire, P., Mesnard, L., Werner, E., Vintejoux, E., Marian, J., Ranaivojaona, S., Bissuel, F., Abdelhadi, M., Hammou, Y., Genet-Villeger, C., Hatchuel, Y., Bachelard, G., Medus, M., Dendale – Nguyen, J., Guimard, T.S., Martha, A., Rouha, M., Perfezou, P., De Saint Martin, L., Jaffuel, S., Buzele, R., Gousseff, M., Cudeville, C., Vitrat, V., Michau, C., Palenzuela, G., Driessen, M., Heller-Roussin, B., Labaune, J.M., Muanza, B., Massardier, J., Partisani, M., Hau, I., Runel-Belliard, C., Brehin, C., Kebaili, K., Lalande, M., Lagree, M., Lacombe, K., Molina, J.-M., Reynes, J., Robineau, O., Raffi, F., Becker, A., Weiss, L., Allègre, T., Pialoux, G., Souala, F., Rami, A., Katlama, C., Cabié, A., Viard, J.-P., Bastides, F., Michel, C., Salmon, D., Lièvre, J-D Le, Sotto, A., Rouveix, E., Naqvi, A., Brégigeon, S., Rodet, R., Simon-Coutelier, A., Esnault, J.-L., Buzelé, R., Stein, A., Godin-Colet, C., Pichancourt, G., Caraux-Paz, P., Zadeh, M Mohseni, Gérard, L., Lascaux-Cametz, C., Bodard, L., Pellegrin, J.-L., Ettahar, N., Uludag, A., Rosenthal, E., Prevoteau du Clary, F., Jaureguiberry, S., Philibert, P., Lecapitaine, A.-L., Chakvetadze, E., Champagne, H., Daneluzzi, V., Goupil de Bouillé, J., Leprêtre, A., Lamaury, I., Darasteanu, I., Abraham, B., Garipuy, D., Berger, J.-L., Schmit, J.-L., Diallo, K., Gourdon, F., Vaillant, O., Gaborieau, V., Doll, J., Quinsat, D., Geffray, L., Girard, J.-J., Houlbert, D., Perronne, V., Klement, E., Antioniotti, O., Rouzioux, C., Avettand-Fenoel, V., Lortholary, O., Boucly, S., Maignan, A., Thiebaut, R., Meyer, L., Boufassa, F., Charles, M.A., Dray-Spira, R., Legeai, C., Amon, V., Benammar, N., Seng, R., Slama, L., Bonnard, P., Chakvetadze, C., L’Yavanc, T., Capeau, J., Vigouroux, C., Fellahi, S., Bastard, J.P., Oksenhendler, E., Bourge, J.F., Bajzik, V., Sereni, D., Lascoux-Combe, C., Taulera, O., Dien, L.V., Delgado, J., Molina, J.M., Saint-Marc, T., Ferret, S., Pavie, J., Bergmann, J.F., Parrinello, M., BLefebvre, Boudraa, C., Diallo, B., Lupin, C., Herson, S., Simon, A., Edeb, N., Guillevin, L., Tahi, T., Pietri, M.P., Tisne-Dessus, D., Jalbert, C., Yeni, P., Matheron, S., Pahlavan, G., Phung, B., El-Alami Talbi, N., Ramani, Z., Catalano, G., Godard, C., Boue, F., Chambrin, V., Bornarel, D., Schoen, H., Carlier, R., Fantin, B., Poder, C., Dhote, R., Bentata, M., Honore, P., Tuyet, Xuan, Delfraissy, J.F., Chaix, F., Rannou, M.T., Levy, Y., Sobel, A., Dumont, C., Abel, S., Pierre-François, S., Beaujolais, V., Poizot-Martin, I., Zaegel-Faucher, O., Debreux, C., Moreau, J., Van Der Gheynst, E., Thiebaut-Drobacheff, M.C., Foltzer, A., Hoen, B., Faucher, J.F., Gil, H., Ragnaud, J.M., Raymond, I., Louis, I., Hessamfar, M., Baillat, V., De Boever, C Merle, Tramoni, C., Soufflet, A., Guadagnin, P., Choutet, P., Mounoury, O., Brosseau, D., Hue, H., May, T., Wassoumbou, S., Stenzel, M., Bouillon, M.P., Yazdanpanah, Y., Huleux, T., Aissi, E., Pavel, S., Rey, D., Fischer, P., Blaison, G., Martinot, M., Pachart, A., Jeanblanc, F., Touraine, J.L., Trepo, C., Miailhes, P., Kouadjo, K., Thoirain, V., Brochier, C., Perre, P., Leautez, S., Esnault, J.L., Suaud, I., Seng, Rémonie, Frange, Pierre, Faye, Albert, Dollfus, Catherine, le Chenadec, Jérôme, Boufassa, Faroudy, Essat, Asma, Goetghebuer, Tessa, Arezes, Elisa, Avettand-Fènoël, Véronique, Bigna, Jean-Joël, Blanche, Stéphane, Goujard, Cécile, Meyer, Laurence, Warszawski, Josiane, and Viard, Jean-Paul

Published
2024
Full Text
View/download PDF

8. Caractéristiques initiales et évolutives des périartérites noueuses associées au syndrome VEXAS et aux leucémies myélo-monocytaires chroniques comparativement aux formes primitives

Author

Cioni, P., primary, Nguyen, Y., additional, Rohmer, J., additional, Dupuy, H., additional, Puéchal, X., additional, Lazaro, E., additional, Pugnet, G., additional, Durel, C.A., additional, Conticini, E., additional, Lifermann, F., additional, Bielefeld, P., additional, Duffau, P., additional, Mahrhofer, H., additional, Régent, A., additional, Guillevin, L., additional, Trefond, L., additional, Agard, C., additional, Allain, J.S., additional, Berezne, A., additional, Mekinian, A., additional, Lacombe, V., additional, and Terrier, B., additional

Published
2023
Full Text
View/download PDF

9. Essai randomisé, contrôle et en double aveugle sur l’impact de la rosuvastatine sur les marqueurs d’athérosclérose infra-clinique chez les patients atteints de vascularite associée aux ANCA

Author

Terrier, B., primary, Pugnet, G., additional, Sirieix, M.E., additional, Quéméneur, T., additional, Puéchal, X., additional, Maurier, F., additional, Néel, A., additional, Benhamou, Y., additional, Bonnotte, B., additional, Schmidt, J., additional, Michon, A., additional, Baudet, A., additional, Charles, P., additional, Cohen-Aubart, F., additional, De Moreuil, C., additional, Dernis, E., additional, Belenotti, P., additional, Ruivard, M., additional, Aumaître, O., additional, Fain, O., additional, Seror, R., additional, Durel, C.A., additional, Jourde-Chiche, N., additional, Lazaro, E., additional, Armengol, G., additional, Bellien, J., additional, Ravaud, P., additional, Baron, G., additional, and Guillevin, L., additional

Published
2023
Full Text
View/download PDF

11. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis

Author

Emmi, G, Bettiol, A, Gelain, E, Bajema, I, Berti, A, Burns, S, Cid, M, Cohen Tervaert, J, Cottin, V, Durante, E, Holle, J, Mahr, A, Del Pero, M, Marvisi, C, Mills, J, Moiseev, S, Moosig, F, Mukhtyar, C, Neumann, T, Olivotto, I, Salvarani, C, Seeliger, B, Sinico, R, Taillé, C, Terrier, B, Venhoff, N, Bertsias, G, Guillevin, L, Jayne, D, Vaglio, A, Emmi G., Bettiol A., Gelain E., Bajema I. M., Berti A., Burns S., Cid M. C., Cohen Tervaert J. W., Cottin V., Durante E., Holle J. U., Mahr A. D., Del Pero M. M., Marvisi C., Mills J., Moiseev S., Moosig F., Mukhtyar C., Neumann T., Olivotto I., Salvarani C., Seeliger B., Sinico R. A., Taillé C., Terrier B., Venhoff N., Bertsias G., Guillevin L., Jayne D. R. W., Vaglio A., Emmi, G, Bettiol, A, Gelain, E, Bajema, I, Berti, A, Burns, S, Cid, M, Cohen Tervaert, J, Cottin, V, Durante, E, Holle, J, Mahr, A, Del Pero, M, Marvisi, C, Mills, J, Moiseev, S, Moosig, F, Mukhtyar, C, Neumann, T, Olivotto, I, Salvarani, C, Seeliger, B, Sinico, R, Taillé, C, Terrier, B, Venhoff, N, Bertsias, G, Guillevin, L, Jayne, D, Vaglio, A, Emmi G., Bettiol A., Gelain E., Bajema I. M., Berti A., Burns S., Cid M. C., Cohen Tervaert J. W., Cottin V., Durante E., Holle J. U., Mahr A. D., Del Pero M. M., Marvisi C., Mills J., Moiseev S., Moosig F., Mukhtyar C., Neumann T., Olivotto I., Salvarani C., Seeliger B., Sinico R. A., Taillé C., Terrier B., Venhoff N., Bertsias G., Guillevin L., Jayne D. R. W., and Vaglio A.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA. Here, we present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in the past few years in understanding the pathogenesis, clinical subphenotypes and differential diagnosis of the disease, as well as the availability of new treatment options. Developed by a panel of European experts on the basis of literature reviews and, where appropriate, expert opinion, the 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of EGPA. These recommendations are primarily intended to be used by healthcare professionals, pharmaceutical industries and drug regulatory authorities, to guide clinical practice and decision-making in EGPA. These guidelines are not intended to limit access to medications by healthcare agencies, nor to impose a fixed order on medication use.

Published
2023

13. Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

Author

Delvino, P, Sardanelli, F, Monti, S, Cohen, P, Puéchal, X, Mouthon, L, Montecucco, C, Guillevin, L, Terrier, B, Paolo Delvino, Federica Sardanelli, Sara Monti, Pascal Cohen, Xavier Puéchal, Luc Mouthon, Carlomaurizio Montecucco, Loïc Guillevin, Benjamin Terrier, Delvino, P, Sardanelli, F, Monti, S, Cohen, P, Puéchal, X, Mouthon, L, Montecucco, C, Guillevin, L, Terrier, B, Paolo Delvino, Federica Sardanelli, Sara Monti, Pascal Cohen, Xavier Puéchal, Luc Mouthon, Carlomaurizio Montecucco, Loïc Guillevin, and Benjamin Terrier

Abstract

Objective: To assess the prevalence and impact on damage accrual of different levels of disease activity in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Methods: Patients with GPA and MPA followed for ≥5 years in 2 different centers were included. Disease activity and damage were assessed using the Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI), respectively. Three levels of remission were defined: complete remission (BVAS = 0, negative for antineutrophil cytoplasmic antibody [ANCA], off treatment), clinical remission off therapy (CROffT; BVAS = 0, positive for ANCA), and clinical remission on therapy (CROnT; BVAS = 0, negative or positive for ANCA, glucocorticoids ≤5 mg/day and/or immunosuppressant). A low disease activity state (LDAS) was defined as 0 < BVAS ≤3, low-dose glucocorticoids (≤7.5 mg/day), and/or immunosuppressant. Remission or LDAS were defined as prolonged when lasting ≥2 consecutive years. Results: A total of 167 patients were included: 128 (76.6%) with GPA, 39 (23.4%) with MPA, mean ± SD age 51.0 ± 16.7 years. During a 5-year follow-up, 10 patients (6.0%) achieved prolonged complete remission, 6 (3.6%) prolonged CROffT, 89 (53.3%) prolonged CROnT, 42 (25.1%) prolonged LDAS, and 20 (12.0%) never achieved LDAS. The VDI score at 5 years progressively worsened according to increasing levels of disease activity targets (complete remission, CROffT, CROnT, and LDAS). The mean ± SD 5-year VDI score was higher in patients not achieving prolonged remission compared to those who did (3.7 ± 2.0 versus 2.2 ± 1.9; P < 0.0001). By multivariate analysis, baseline ear, nose, and throat (P = 0.006), and lung involvement (P = 0.047) were negative predictors of prolonged remission. Conclusion: More than 60% of patients with GPA/MPA achieved prolonged remission, which was associated with better long-term outcomes. In contrast, prolonged LDAS correlated with increased damage accrual and was

Published
2023

15. Rituximab versus cyclophosphamide en traitement d’induction de la granulomatose avec polyangéite : essai thérapeutique émulé

Author

Puéchal, X., primary, Iudici, M., additional, Perrodeau, E., additional, Bonnotte, B., additional, Lifermann, F., additional, Le Gallou, T., additional, Karras, A., additional, Blanchard-Delaunay, C., additional, Quéméneur, T., additional, Aouba, A., additional, Aumaître, O., additional, Cottin, V., additional, Hamidou, M., additional, Ruivard, M., additional, Cohen, P., additional, Mouthon, L., additional, Guillevin, L., additional, Ravaud, P., additional, Porcher, R., additional, and Terrier, B., additional

Published
2022
Full Text
View/download PDF

16. Efficacité à long terme des schémas d’induction de la rémission au cours de la granulomatose éosinophilique avec polyangéite : résultats de l’essai REOVAS

Author

Dutertre, M., primary, Pugnet, G., additional, De Moreuil, C., additional, Bonnotte, B., additional, Benhamou, Y., additional, Chauveau, D., additional, Diot, E., additional, Duffau, P., additional, Limal, N., additional, Néel, A., additional, Urbansky, G., additional, Jourde-Chiche, N., additional, Fauchais, A.L., additional, Dossier, A., additional, Schleinitz, N., additional, Jilet, L., additional, Guillevin, L., additional, Abdoul, H., additional, Puéchal, X., additional, and Terrier, B., additional

Published
2022
Full Text
View/download PDF

20. Étude des granulomatoses avec polyangéites réfractaires au traitement d’induction

Author

Sorin, B., primary, Iudici, M., additional, Guerry, M.J., additional, Samson, M., additional, Bielefeld, P., additional, Maillet, T., additional, Nouvier, M., additional, Karras, A., additional, Christian, L., additional, Durel, C.A., additional, Fabre, M., additional, Charles, P., additional, Lanteri, A., additional, Pugnet, G., additional, Riviere, F., additional, Le Gueno, G., additional, Guillevin, L., additional, Puéchal, X., additional, and Terrier, B., additional

Published
2022
Full Text
View/download PDF

21. Performance de modèles de prédiction du risque de rechute et d’infection sévère à la fin du traitement d’entretien par rituximab à 18 mois au cours des vascularites à ANCA

Author

Delestre, F., primary, Charles, P., additional, Samson, M., additional, Néel, A., additional, Faguer, S., additional, Karras, A., additional, Lifermann, F., additional, Godmer, P., additional, Hanrotel-Saliou, C., additional, Martin-Silva, N., additional, Pugnet, G., additional, Maurier, F., additional, Le Gallou, T., additional, Quéméneur, T., additional, Méaux-Ruault, N., additional, Viallard, J.F., additional, Puéchal, X., additional, Guillevin, L., additional, Porcher, R., additional, and Terrier, B., additional

Published
2022
Full Text
View/download PDF

22. Atteintes valvulaires cardiaques des vascularites à ANCA : étude multicentrique rétrospective et revue systématique de la littérature

Author

Jeantin, L., primary, Lenfant, T., additional, Bataille, P., additional, De Boysson, H., additional, Cathébras, P., additional, Agard, C., additional, Faguer, S., additional, Deschartres, A., additional, Poindron, V., additional, Ruivard, M., additional, Martin-Silva, N., additional, Monge, M., additional, Guillevin, L., additional, Puéchal, X., additional, Terrier, B., additional, and Charles, P., additional

Published
2022
Full Text
View/download PDF

24. Séquelles à long terme au cours de la granulomatose éosinophilique avec polyangéite : données issues d’une étude rétrospective multicentrique de 845 patients

Author

Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Durel, C, Vaglio, A, Emmi, G, Guillevin, L, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Salvarani, C., Kahn, J. E., Durel, C. A., Vaglio, A., Emmi, G., Guillevin, L., Terrier, B., Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Durel, C, Vaglio, A, Emmi, G, Guillevin, L, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Salvarani, C., Kahn, J. E., Durel, C. A., Vaglio, A., Emmi, G., Guillevin, L., and Terrier, B.

Published
2020

26. Émulation d’un essai clinique comparant les corticoïdes versus les corticoïdes plus le cyclophosphamide au cours de la granulomatose éosinophilique avec polyangéite sévère

Author

Sorin, B., Papo, M., Sinico, R.A., Teixeira, V., Venhoff, N., Urban, M.L., Mahrhold, J., Locatelli, F., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Marvisi, C., Samson, M., Barba, T., Jayne, D., Troilo, A., Thiel, J., Hellmich, B., Monti, S., Montecucco, C., Salvarani, C., Kahn, J.E., Durel, C.A., Mouthon, L., Guillevin, L., Giacomo, E., Vaglio, A., Porcher, R., and Terrier, B.

Published
2024
Full Text
View/download PDF

29. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

Author

Couffignal, Camille, Kolta, Sami, Flamant, Martin, Cazanave, Charles, Haymann, Jean-Philippe, Mentre, France, Duval, Xavier, Leport, Catherine, Raffi, Francois, Chêne, G., Salamon, R., Moatti, J., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Cuzin, L., Dupon, M., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Hardel, L., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Assuied, A., Carrieri, P., Habak, S., Couturier, F., Jadand, C., Perrier, A., Préau, M., Protopopescu, C., Schmit, J.L., Chennebault, J.M., Faller, J.P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Neau, D., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Levy, Y., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Chidiac, C., Grégoire, V., Reynes, J., Fuzibet, J., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P.M., Guillevin, L., Herson, S., Molina, J.M., Pialoux, G., Sain, O., Sellier, P., Roblot, F., Bani-Sadr, F., Michelet, C., Lucht, F., Debord, C., Martin, T., de Jaureguiberry, J.P., Bernard, L., Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Physiologie [Bichat-Claude Bernard], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service des Maladies Infectieuses et Tropicales A [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Bell Labs (BELL), Lucent Technologies, Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service de virologie et d'immunologie biologique, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses et Tropicales [CHU Raymond Poincaré], Hôpital Raymond Poincaré [AP-HP], Centre Hospitalier Libourne, Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Radiation Oncology, Université Catholique de Louvain = Catholic University of Louvain (UCL), GERES - Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux - Research Group for the Prevention of Occupational Infections in Healthcare Workers [Paris, France], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Reims (CHU Reims), University Hospital and University Jean Monnet, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Groupe d'Étude sur le Risque d'Exposition des Soignants aux agents infectieux (GERES), Cholley, Pascal, and Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière]

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Nevirapine, nevirapine, Immunology, Cumulative Exposure, HIV Infections, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Bone Density, Virology, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, 030304 developmental biology, Bone mineral, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Incidence (epidemiology), HIV, virus diseases, Odds ratio, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Cross-Sectional Studies, Infectious Diseases, Cohort, HIV-1, Coinfection, Reverse Transcriptase Inhibitors, Female, bone mineral density, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, medicine.drug
Abstract

International audience; We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA

Published
2020

32. Pulmonary vasculitides

Author

Mouthon, L., Lhote, F., Guillevin, L., Ansell, B. M., editor, Bacon, P. A., editor, Lie, J. T., editor, and Yazici, H., editor

Published
1996
Full Text
View/download PDF

35. Rituximab en traitement d’entretien des vascularites à ANCA: analyse poolée et suivi à long terme des 277 patients suivis dans les essais prospectifs randomisés contrôlés MAINRITSAN

Author

Delestre, F., primary, Charles, P., additional, Porcher, R., additional, Samson, M., additional, Néel, A., additional, Faguer, S., additional, Karras, A., additional, Lifermann, F., additional, Godmer, P., additional, Hanrotel-Saliou, C., additional, Martin-Silva, N., additional, Pugnet, G., additional, Maurier, F., additional, Le Gallou, T., additional, Méaux-Ruault, N., additional, Viallard, J.F., additional, Hachulla, E., additional, Puéchal, X., additional, Guillevin, L., additional, and Terrier, B., additional

Published
2021
Full Text
View/download PDF

37. Intérêt pronostique d’une évaluation informatisée et automatisée de l’atteinte pulmonaire interstitielle au scanner au cours de la sclérodermie systémique

Author

Le Gall, A., primary, Régent, A., additional, Mouthon, L., additional, Revel, M.P., additional, Chassagnon, G., additional, Hoang-Thi, T.N., additional, Dinh Xuan, A.T., additional, Dunogué, B., additional, Vakalopoulou, M., additional, Porcher, R., additional, Paule, R., additional, London, J., additional, Berezne, A., additional, Guillevin, L., additional, Cohen, P., additional, Le Guern, V., additional, Chaigne, B., additional, and Groh, M., additional

Published
2021
Full Text
View/download PDF

40. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

Author

Lortholary, Olivier, Roussillon, Caroline, Boucherie, Céline, Padoin, Christophe, Chaix, Marie-Laure, Breton, Guillaume, Rami, Agathe, Veziris, Nicolas, Patey, Olivier, Caumes, Eric, May, Thierry, Molina, Jean-Michel, Robert, Jérome, Tod, Michel, Fagard, Catherine, Chêne, Geneviève, Aumaître, H., Borsato, F., Malet, M., Médus, M., Moreau, L., Neuville, S., Saada, M., Abgrall, S., Ahoudji, D., Balmard, L., Bentata, M., Bouchaud, O., Boudribila, A., Cailhol, J., Dhote, R., Djebbar, R., Gros, H., Honoré, P., Huynh, T., Krivitzky, A., Mansouri, R., Pizzocolo, C., Rouges, F., Viot, E., Amar, B., Bantsimba, J., Dellion, S., Patey, O., Richier, L., Dupon, M., Dutronc, H., Neau, D., Ragnaud, J. M., Raymond, I., Boucly, S., Gailhoustet, L., Lortholary, O., Maignan, A., Touam, F., Viard, J. P., Bergmann, J. F., Boulanger, E., Delcey, V., Diemer, M., Durel, A., Jouade, F., Parrinello, M., Rami, A., Sellier, P., Brazille, P., Leclerc, C., Welker, Y., Bernard, L., Berthé, H., Perronne, C., Salomon, J., de Truchis, P., Bolliot, C., Couzigou, C., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Chakvetadze, C., Fontaine, C., LʼYavanc, T., Maresca, A., Pialoux, G., Slama, L., Tuna, L., Bornarel, D., Boué, F., Chassaing, A., Chaiba-Berroukeche, L., Chambrin, V., Delavalle, A. M., Galanaud, P., Levy, A., Pignon, C., Bonnet, D., Ecobichon, J. L., Fournier, I., Fraquiero, G., Gerbe, J., Gervais, A., Guiyedi, V., Iordache, L., Joly, V., Klutse, P., Laurichesse, J. J., Leport, C., Onanga, M., Pahlaval, G., Phung, B. C., Ralaimazava, P., Yeni, P., Almasi, F., Basler, M., Benammar, N., Brunes, A., Guérin, C., Guillevin, L., Meddour, R., Salmon, D., Spiridon, G., Tahi, T., Bloch, M., Ferreira, C., Mahe, I., Manceron, V., Minozzi, C., Mortier, E., Simonpoli, A. M., Vinceneux, P., Zeng Ai, F., Chesnel, C., Dominguez, S., Jouve, P., Lascaux-Cametz, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Sobel, A., Bentaleb, N., Blondin-Diop, A., Bonmarchand, M., Bossi, P., Brancon, C., Breton, G., Bricaire, F., Caby, F., Canestri, A., Clavel, C., Edeb, N., Herson, S., Iguertsira, M., Katlama, C., Kouadio, H., Lagarde, P., Lopez, J. L., Marguet, F., Martinez, V., Remidi, H., Simon, A., Souchon, J. F., Valantin, M. A., Bollens, D., Girard, P. M., Lagneau, J. L., Lefebvre, B., Mouchotte, R., Ouazene, Z., Sebire, M., Theveny-Christiany, A., Valin, N., Bourgarit, A., de Castro, N., Delgado, J., Ferret, S., Lascoux-Combe, C., Molina, J. M., Parlier, S., Pavie, J., Pintado, C., Ponscarme, D., Rachline, A., Sereni, D., Taulera, O., de Verdiere, C., Vincent, F., Bernard, N., Bonarek, M., Bonnet, F., Delaune, J., Lacoste, D., Louis, I., Malvy, D., Mercier, P., Morlat, P., Pertusa, M. C., Schottey, M., Chanteloube, N., Eden, A., Le Moing, V., Makilson, A., de Boever, C. Merle, Reynes, J., Turrière, C., Tramoni, C., Vidal, M., Anavena, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, J., Boutoille, D., Brosseau, D., Brunct, C., Colas, M., Feuillebois, N., Hüe, H., Launay, E., le Houssine, P. Morineau, Raffi, F., Reliquet, V., Cua, E., Dellamonica, P., Durant, J., Rahelinirina, V., Arvieux, C., Chapplain, J. M., Fily, F., Labbay, E., Michelet, C., Morin, F., Peaucelle, C., Revest, M., Ratajczak, M., Souala, F., Tattevin, P., Thomas, R., Alvarez, M., Balsarin, F., Bonnet, E., Busato, F., Cuzin, L., Marche, D., Marchou, B., Massip, P., Obadia, M., Porte, L., Aissi, E., Ajana, F., Alcaraz, I., Baclet, V., Dubus, S., Gérard, Y., Guerroumi, H., Huleux, T., Lahouste, A., Marien, M. C., Melliez, H., Mouton, Y., Pennel, M. P., Valette, M., Viget, N., Yazdanpanah, Y., Bevilacqua, S., Boyer, L., Lecompte, T., Letranchant, L., May, T., Rabaud, C., Thomas, L., Vancon, R., Wassoumbou, S., Abboud, P., Borsa-Lebas, F., Caron, F., Debab, Y., Etienne, M., Faucon, M., Gueit, I., Brouqui, P., Mokhtari, S., Moreau, J., Schlojsers, M., Vandergheynst, E., Chousterman, M., Delacroix-Szmania, I., El Harrar, B., Garrait, V., Joannes, S., Luquet-Besson, I., Mouchet, M., Richier, L., Stevens, A. Blase, Dupont, C., Maresca, A. Freire, Greffe, S., Hanslik, T., Landi, B., Leporrier, J., Rouveix, E., Toth, K., El Mansouf, L., Khuong-Josses, M. A., Méchali, D., Le Besnerais, J. Phalip, Taverne, B., Barclay, F., Fain, O., Flexor, G., Stirnemann, J., Tassi, S., Levast, M., Rogeaux, O., Raffenot, D., Tous, J., Lortholary, O., Bouchaud, O., Chaix, M. L., Chêne, G., Couffin-Cadiergues, S., Dupon, M., Fagard, C., Joly, V., Launay, O., Molina, J. M., Robert, J., Roussillon, C., Rouzioux, C., Tod, M., Yazdanpanah, Y., Lortholary, O., Breton, G., Caumes, E., May, T., Roussillon, C., Veziris, N., Badets, M., Boucherie, C., Fagard, C., Chêne, G., Roussillon, C., Terras, N., Guérin, C., Altare, F., Bourgarit, A., Carcelain, G., Trylesinski, A., Aubron-Olivier, C., Nguyen, T., and Bennai, Y.

Published
2016
Full Text
View/download PDF

44. La granulomatose éosinophilique avec polyangéite (Churg-Strauss) avec positivité des ANCA-PR3 existe-t-elle réellement ?

Author

Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Samson, M, Jayne, D, Hellmich, B, Salvarani, C, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Samson, M., Jayne, D., Hellmich, B., Salvarani, C., Guillevin, L., Emmi, G., Vaglio, A., Terrier, B., Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Samson, M, Jayne, D, Hellmich, B, Salvarani, C, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Samson, M., Jayne, D., Hellmich, B., Salvarani, C., Guillevin, L., Emmi, G., Vaglio, A., and Terrier, B.

Published
2019

45. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

Author

Lyons, P. A., Peters, J. E., Alberici, F., Liley, J., Coulson, R. M. R., Astle, W., Baldini, C., Bonatti, F., Cid, María Cinta, Elding, H., Emmi, G., Epplen, J., Guillevin, L., Jayne, D. R. W., Jiang, T., Gunnarsson, I., Lamprecht, P., Leslie, S., Little, M. A., Martorana, D., Moosig, F., Neumann, T., Ohlsson, S., Quickert, S., Ramirez, G. A., Rewerska, B., Schett, George, Sinico, R. A., Szczeklik, W., Tesar, Vladimir, Vukcevic, D., Akil, M., Barratt, J., Basu, N., Butterworth, A. S., Bruce, I., Clarkson, M., Conlon, N., DasGupta, B., Doulton, T. W. R., Espígol-Frigolé, Georgina, Flossmann, O., Gabrielli, A., Gasior, J., Gregorini, G., Guida, G., Hernández Rodríguez, José, Hruskova, Z., Hudson, A., Knight, A., Lanyon, P., Luqmani, R., Magliano, M., Manfredi, A. A., Marguerie, C., Maritati, F., Marvisi, C., McHugh, N. J., Molloy, E., Motyer, A., Mukhtyar, C., Padyukov, Leonid, Pesci, Alberto, Prieto-Gonzalez, S., Ramentol-Sintas, Marc, Reis, P., Roccatello, D., Rovere-Querini, P., Salvarani, C., Santarsia, F., Solans, Roser, Soranzo, N., Taylor, J., Wessels, J., Zwerina, J., Terrier, B., Watts, R. A., Vaglio, A., Holle, J. U., Wallace, C., Smith, K. G. C., Universitat Autònoma de Barcelona, Lyons, P. A., Peters, J. E., Alberici, F., Liley, J., Coulson, R. M. R., Astle, W., Baldini, C., Bonatti, F., Cid, M. C., Elding, H., Emmi, G., Epplen, J., Guillevin, L., Jayne, D. R. W., Jiang, T., Gunnarsson, I., Lamprecht, P., Leslie, S., Little, M. A., Martorana, D., Moosig, F., Neumann, T., Ohlsson, S., Quickert, S., Ramirez, G. A., Rewerska, B., Schett, G., Sinico, R. A., Szczeklik, W., Tesar, V., Vukcevic, D., Akil, M., Barratt, J., Basu, N., Butterworth, A. S., Bruce, I., Clarkson, M., Conlon, N., Dasgupta, B., Doulton, T. W. R., Espigol-Frigole, G., Flossmann, O., Gabrielli, A., Gasior, J., Gregorini, G., Guida, G., Hernandez-Rodriguez, J., Hruskova, Z., Hudson, A., Knight, A., Lanyon, P., Luqmani, R., Magliano, M., Manfredi, A. A., Marguerie, C., Maritati, F., Marvisi, C., Mchugh, N. J., Molloy, E., Motyer, A., Mukhtyar, C., Padyukov, L., Pesci, A., Prieto-Gonzalez, S., Ramentol-Sintas, M., Reis, P., Roccatello, D., Rovere-Querini, P., Salvarani, C., Santarsia, F., Solans-Laque, R., Soranzo, N., Taylor, J., Wessels, J., Zwerina, J., Terrier, B., Watts, R. A., Vaglio, A., Holle, J. U., Wallace, C., Smith, K. G. C., Lyons, P, Peters, J, Alberici, F, Liley, J, Coulson, R, Astle, W, Baldini, C, Bonatti, F, Cid, M, Elding, H, Emmi, G, Epplen, J, Guillevin, L, Jayne, D, Jiang, T, Gunnarsson, I, Lamprecht, P, Leslie, S, Little, M, Martorana, D, Moosig, F, Neumann, T, Ohlsson, S, Quickert, S, Ramierez, G, Rewerska, B, Schett, G, Sinico, R, Szczeklik, W, Tesar, V, Vukcevic, D, Akil, M, Barratt, J, Basu, N, Butterworth, A, Bruce, I, Clarkson, M, Conlon, N, Dasgupta, B, Doulton, T, Espigol-Frigole, G, Flossmann, O, Gabrielli, A, Gasior, J, Gregorini, G, Guida, G, Hernandez-Rodriguez, J, Hruskova, Z, Hudson, A, Knight, A, Lanyon, P, Luqmani, R, Magliano, M, Manfredi, A, Marguerie, C, Maritati, F, Marvisi, C, Mchugh, N, Molloy, E, Motyer, A, Mukhtyar, C, Padyukov, L, Pesci, A, Prieto-Gonzalez, S, Ramentol-Sintas, M, Reis, P, Roccatello, D, Rovere-Querini, P, Salvarani, C, Santarsia, F, Solans-Laque, R, Soranzo, N, Taylor, J, Wessels, J, Zwerina, J, Terrier, B, Watts, R, Vaglio, A, Holle, J, Wallace, C, Smith, K, and United Kingdom Research and Innovation

Subjects
0301 basic medicine, Candidate gene, Antineutrophil Cytoplasmic, General Physics and Astronomy, Genome-wide association study, Autoimmunity, Genome-wide association studies, 0302 clinical medicine, Rheumatic diseases, immune system diseases, Eosinophilic, Eosinophilia, lcsh:Science, education.field_of_study, Multidisciplinary, Genome-wide association, eosinophilic granulomatosis with polyangiitis, ANCA status, 3. Good health, medicine.symptom, Vasculitis, Granulomatosis with polyangiitis, Antibodies, Antineutrophil Cytoplasmic, Eosinophils, Genetic Association Studies, Granulomatosis with Polyangiitis, Humans, Mendelian Randomization Analysis, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, European Vasculitis Genetics Consortium, Science, Population, General Biochemistry, Genetics and Molecular Biology, Article, Antibodies, 03 medical and health sciences, medicine, Immunogenetics, education, Rheumatology and Autoimmunity, Anti-neutrophil cytoplasmic antibody, 030203 arthritis & rheumatology, Reumatologi och inflammation, business.industry, General Chemistry, medicine.disease, respiratory tract diseases, 030104 developmental biology, Immunology, EGPA, HLA, ANCA, genetics, lcsh:Q, business
Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA., Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterised by asthma, eosinophilia and vasculitis. Here, the authors describe a genome-wide association study of EGPA that reveals clinical and genetic differences between subgroups stratified by autoantibody status (ANCA).

Published
2019

46. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

Author

Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert AM, Groh M, Girszyn N, Taillé C, Maurier F, Cottin V, de Moreuil C, Germain V, Samson M, Jachiet M, Denis L, Rieu V, Smets P, Pugnet G, Deroux A, Durel CA, Aouba A, Cathébras P, Deligny C, Faguer S, Gil H, Godeau B, Lifermann F, Phin-Huynh S, Ruivard M, Bonniaud P, Puéchal X, Kahn JE, Thiel J, Dagna L, Guillevin L, Vaglio A, Emmi G, Terrier B, French Vasculitis Study Group (FVSG), the European EGPA Study Group., Canzian, A, Venhoff, N, Urban, Ml, Sartorelli, S, Ruppert, Am, Groh, M, Girszyn, N, Taillé, C, Maurier, F, Cottin, V, de Moreuil, C, Germain, V, Samson, M, Jachiet, M, Denis, L, Rieu, V, Smets, P, Pugnet, G, Deroux, A, Durel, Ca, Aouba, A, Cathébras, P, Deligny, C, Faguer, S, Gil, H, Godeau, B, Lifermann, F, Phin-Huynh, S, Ruivard, M, Bonniaud, P, Puéchal, X, Kahn, Je, Thiel, J, Dagna, L, Guillevin, L, Vaglio, A, Emmi, G, Terrier, B, and French Vasculitis Study Group (FVSG), the European EGPA Study Group.

Subjects
Adult, Male, medicine.medical_specialty, Immunology, Birmingham Vasculitis Activity Score, Omalizumab, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Interquartile range, Recurrence, Internal medicine, medicine, Immunology and Allergy, Humans, Immunologic Factors, 030212 general & internal medicine, Treatment Failure, Adverse effect, Glucocorticoids, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, business.industry, Middle Aged, medicine.disease, Asthma, Treatment Outcome, Rituximab, Female, Vasculitis, business, Granulomatosis with polyangiitis, Mepolizumab, medicine.drug
Abstract

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was 2 (IQR 1-5). In patients receiving RTX, the median BVAS declined both at 6 months (median 1, IQR 0-4.5) and at 12 months (median 0, IQR 0-2), and the frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 49%, 24%, 24%, and 3%, respectively. For the treatment of glucocorticoid (GC)-dependent asthma, patients who received MEPO had a much better GC-sparing effect and overall response than did patients who received OMA. The frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 15%, 33%, 48%, and 4%, respectively, in the OMA group and 78%, 10%, 8%, and 4%, respectively, in the MEPO group. Remission rates at 12 months were 76% and 82% among patients receiving MEPO at a doses of 100 mg and 300 mg, respectively. CONCLUSION These results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first-line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.

Published
2020

48. Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis

Author

Mettler, C., primary, Durel, CA., additional, Guilpain, P., additional, Bonnotte, B., additional, Cohen-Aubart, F., additional, Hamidou, M., additional, Lega, JC., additional, Guern, V. Le, additional, Lifermann, F., additional, Poindron, V., additional, Pugnet, G., additional, Servettaz, A., additional, Puéchal, X., additional, Guillevin, L., additional, and Terrier, L., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results